Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02242045 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 6 | Gilead SciencesINDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT01938612 | A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | completed | Phase 1 | 269 | AstraZenecaINDUSTRY | 3 | Mar 12, 2021 |
| clinicaltrials |
| NCT01440920 | A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 9 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT02293993 | Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 21 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2021 | clinicaltrials |
| NCT01475370 | Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) | completed | Phase 1 | 18 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT01801930 | A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer | completed | Phase 1 | 24 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT02699749 | A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors | completed | Phase 1 | 80 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02740270 | Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas | completed | Phase 1 | 92 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 21, 2021 | clinicaltrials |
| NCT02377752 | A Study of Olaratumab in Japanese Participants With Advanced Cancer | completed | Phase 1 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02900157 | Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 42 | MedImmune LLCINDUSTRY | 2 | Jan 14, 2021 | clinicaltrials |
| NCT01268059 | A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 99 | MedImmune LLCINDUSTRY | 7 | Dec 23, 2020 | clinicaltrials |
| NCT00622258 | A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01468688 | A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT01471548 | Phase I Dose Escalating Study of TKI258 | completed | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03158272 | A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread | completed | Phase 1 | 19 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00410358 | A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor. | completed | Phase 1 | 19 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00441610 | An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor | completed | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00739414 | Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01208831 | An East Asian Study of LDE225 | completed | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01546428 | A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 44 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01613976 | A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01634763 | Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) | completed | Phase 1 | 22 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01898845 | A Phase I Study of LEE011 in Asian Patients | completed | Phase 1 | 17 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01968915 | Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02375958 | PCA062 in pCAD-positive Tumors. | completed | Phase 1 | 47 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 19, 2020 | clinicaltrials |
| NCT02988440 | Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01911936 | A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 12 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT02078609 | A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 70 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 17, 2020 | clinicaltrials |
| NCT02160951 | Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies | completed | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00674102 | An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01132625 | Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | completed | Phase 1 | 37 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01195376 | A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01285453 | Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01613950 | PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT00384228 | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01064089 | Dose Escalation of HSP990 in Japan/Korea | terminated | Phase 1 | 17 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01279473 | Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) | completed | Phase 1 / Phase 2 | 42 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01283503 | A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01387321 | A Study of BYL719 in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01697605 | A Phase I Study of Oral BGJ398 in Asian Patients | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 8, 2020 | clinicaltrials |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | terminated | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT03980821 | A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 10 | AstraZenecaINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00389051 | A Phase I Study of Bendamustine Hydrochloride in Patients With Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 9 | SymBio PharmaceuticalsINDUSTRY | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00836888 | ONO-4538 Phase I Study in Patients With Advanced Malignant Solid Tumors in Japan | completed | Phase 1 | 17 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01469130 | A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors | completed | Phase 1 | 21 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02451930 | A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC | completed | Phase 1 | 71 | Eli Lilly and CompanyINDUSTRY | 4 | Oct 5, 2020 | clinicaltrials |
| NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | completed | Phase 1 / Phase 2 | 40 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03289533 | A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | completed | Phase 1 | 22 | PfizerINDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials